The National Institutes of Health (NIH) awarded Dr. Girgis Obaid $723,942 for his research on Molecular Imaging-directed Bioengineering of Nanoconjugates as Adaptable Tumor Targeting Platforms. The project will utilize quantitative dual-tracer molecular binding imaging as the primary criterion for defining in vivo molecular selectivity of modular nanoconjugates at the cellular level, and will thus accurately direct their tailored bioengineering to enhance outcomes of heterogeneously-targeted head and neck cancer phototherapies.